Trial Profile

An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 18 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ulotaront (Primary)
Indications Schizophrenia
Focus Adverse reactions; Registrational
Acronyms DIAMOND 3
Sponsors Otsuka Pharmaceutical Development & Commercialization; Sumitomo Pharma America

Most Recent Events

19 Dec 2023 This trial has been completed in Bulgaria, according to European Clinical Trials Database.
13 Dec 2023 Status changed from recruiting to discontinued.
03 Dec 2023 This trial has been completed in Latvia , according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com